Asian registry of brachytherapy for cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The registry uses a retrospective cohort design to collect consecutive cases from participating Asian centers over a 12‑month period, aiming for about 1,000 patients. It captures the full range of brachytherapy practice (2D to 3D), imaging modalities used for planning (X‑ray, CT, MRI, ultrasound), external beam radiation details, concurrent chemotherapy, and overall treatment time. Patient demographics, contouring practices, and institutional treatment patterns will be recorded, with monitoring and quality assurance procedures to ensure data completeness and integrity. Data handling protocols will protect privacy and a publication policy will guide multi‑institutional analysis and reporting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype.
* Planned for treatment with definitive chemo-radiation and brachytherapy. (X- ray,CT, CT-Ultrasound or MRI based).

Exclusion Criteria:

* Neuroendocrine cancer of the cervix or other rare histology subtypes.
* Patients with metastatic cervix cancer and not planned for radical doses of pelvic RT/brachytherapy may be excluded.
* Patients undergoing postoperative RT or RT for recurrent disease should be excluded.

Where it's running

• Tata Memorial Center
  Mumbai, Maharashtra, India Recruiting
• Gunma University
  Maebashi, Japan, Japan Not yet recruiting
• Juntendo University
  Tokyo, Japan, Japan Not yet recruiting
• Mahidol University
  Bangkok, Thailand, Thailand Not yet recruiting
• Chiang Mai University
  Chiang Mai, Thailand, Thailand Not yet recruiting

Study contacts

• Study coordinator: Dr. Supriya Chopra
• Email: supriyasastri@gmail.com
• Phone: 9930958309

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Induction pembrolizumab with carboplatin/paclitaxel before chemoradiation and pembrolizumab maintenance for high‑risk locally advanced cervical cancer

  This phase III trial tests whether giving pembrolizumab with carboplatin and paclitaxel before chemoradiation, then continuing pembrolizumab as maintenance, helps people with locally advanced high‑risk cervical cancer stay free of progression longer than starting pembrolizumab during chemoradiation.

  Recruiting at 340 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 346 other locations · NCT07061977

• Radiomic MRI model to predict response to chemoradiotherapy in locally advanced cervical cancer

  This project tests whether MRI-based radiomic features can predict how women with locally advanced cervical cancer will respond to combined chemotherapy and radiation.

  Recruiting Centre Hospitalier Universitaire de Nīmes · Nîmes, Gard · NCT07305727

• Adaptive radiation therapy for cervical cancer

  This study is testing if a new type of radiation therapy can help reduce stomach and bowel problems in people with advanced cervical cancer who are also getting chemotherapy.

  Recruiting at 5 sites Varian, a Siemens Healthineers Company · Burmingham, Alabama and 4 other locations · NCT05197881

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.